Concepedia

Malidi Ahamadi

MA

Statistics

Publications

16

Citations

858

H-Index

15

Active since

2010

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

Roche (Switzerland)

Critical Path Institute

Biogen (United States)

Malidi Ahamadi is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacy, pharmacokinetic modeling, and pharmacology.

ORCID

Publications per year

2010–2024

16

Publications

16

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee, David C. Turner, Enriqueta Felip et al. · Annals of Oncology · 2016 · 162 citations · Full text

, , +12

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

Malidi Ahamadi, Tomoko Freshwater, Marita Prohn et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 150 citations · Full text

, , +15

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Hongshan Li, Jingyu Yu, Chao Liu et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 138 citations

, , +11

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma

MS Chatterjee, Jeroen Elassaiss‐Schaap, Andreas Lindauer et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 82 citations · Full text

, , +17

Prediction of Concentration–Time Profile and its Inter-Individual Variability following the Dermal Drug Absorption

Sebastian Polak, Cyrus Ghobadi, Himanshu Mishra et al. · Journal of Pharmaceutical Sciences · 2012 · 67 citations · Full text

, , +16

1–5 of 16